Evidence map›Paper›PMID 38127246›Full record

SynthesisSupportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer2023

2023 updated MASCC/ESMO consensus recommendations: prevention of nausea and vomiting following high-emetic-risk antineoplastic agents.

Jørn Herrstedt, L Celio, P J Hesketh, L Zhang, R Navari, A Chan, M Saito, R Chow, M Aapro

Open access · hybridAbstract readSystematic ReviewConsensus Statement
PubMed Full text at PMC Publisher
In one paragraph

Synthesis in Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers, 7 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
22citing papers in PubMed, 7 pooled it
10.2field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

22 citing papers in PubMed, 7 syntheses or guidelines pooled it, 32 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Multi-day vs single-day dexamethasone for the prophylaxis of chemotherapy-induced nausea and vomiting: systematic review and meta-analysis.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2024
    Pooled it
  7. Pooled it
  8. Trial
  9. Trial
  10. Article
  11. Review
  12. TTD expert consensus on emesis in gastric cancer: evidence-based strategies for prevention and treatment.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2026
    Review
  13. Article
  14. Article
  15. Article
  16. Review
  17. Article
  18. Article
  19. Reply to L. Celio et al.British journal of cancer · 2024
    Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 7 institutions in 6 countries.

Jørn HerrstedtDepartment of Clinical Oncology, Zealand University Hospital, Sygehusvej 10, DK-4000, Roskilde, Denmark. jherr@regionsjaelland.dk.ORCID https://orcid.org/0000-0002-8844-6546
L Celio, Milan, Italy.
P J HeskethDivision of Hematology Oncology, Lahey Hospital and Medical Center, Burlington, MA, USA.
L ZhangState Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University Cancer Center, Guangzhou, China.
R NavariWorld Health Organization, Birmingham, Alabama, USA.
A ChanDepartment of Clinical Pharmacy Practice, School of Pharmacy & Pharmaceutical Sciences, University of California Irvine, Irvine, CA, USA.
M SaitoDepartment of Breast Oncology, Juntendo University School of Medicine, Tokyo, Japan.
R ChowTemerty Faculty of Medicine, University of Toronto, Toronto, ON, Canada.
M AaproGenolier Cancer Center, Genolier, Switzerland.
Clinique de Genolier · CHJuntendo University · JPLahey Hospital and Medical Center · USSun Yat-sen University · CNUniversity of California, Irvine · USUniversity of Toronto · CAZealand Institute of Business and Technology · DK

Funding

World Health Organization 001
6 · The paper itself

Abstract

purposeThis systematic review updates the MASCC/ESMO recommendations for high-emetic-risk chemotherapy (HEC) published in 2016-2017. HEC still includes cisplatin, carmustine, dacarbazine, mechlorethamine, streptozocin, and cyclophosphamide in doses of > 1500 mg/m

methodsA systematic review report following the PRISMA guidelines of the literature from January 1, 2015, until February 1, 2023, was performed. PubMed (Ovid), Scopus (Google), and the Cochrane Database of Systematic Reviews were searched. The literature search was limited to randomized controlled trials, systematic reviews, and meta-analyses.

resultsForty-six new references were determined to be relevant. The main topics identified were (1) steroid-sparing regimens, (2) olanzapine-containing regimens, and (3) other issues such as comparisons of antiemetics of the same drug class, intravenous NK

conclusionThere is no need to prescribe steroids (dexamethasone) beyond day 1 after AC HEC, whereas a 4-day regimen is recommended in non-AC HEC. Olanzapine is now recommended as a fixed part of a four-drug prophylactic antiemetic regimen in both non-AC and AC HEC. No major differences between 5-HT

Indexed as

AntiemeticsAntineoplastic AgentsAnthracyclinesCyclophosphamideEmeticsFemaleHumansNauseaOlanzapineVomitingAnthracyclinesAntiemeticsAntineoplastic AgentsCyclophosphamideEmeticsOlanzapineAntiemeticsGuidelineHECHigh-emetic-risk chemotherapyNauseaVomiting

Identifiers

PMID38127246
PMCPMC10739516
OpenAlexW4390051648

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.